Loss-of-function mutations in the tumor suppressor PTEN, occurring in 80–95% of Type I endometrial carcinomas, remove its antagonistic effects on PI3K, leading to constitutive AKT activation, enhanced cell survival, and resistance to apoptosis. This evidence concerns the gene PTEN and endometrial carcinoma.